Reduction of Tumor Burden minimal through the Administration of ccr1 antagonists in combination with inhibitors of pd-1 and pd-l1 inhibitors

摘要

This application provides methods to reduce the minimum tumor, tumor growth, tumor propulsion and / or metastasis load in patients with solid tumors (such as triple tumor). These methods include combining the number of effective treatments for PD-L1 inhibitors or PD-1 inhibitors with the opposite cube of a small molecular chemoreceptor that blocks CCR1. Claim 4: any method of claims 1 to 3, wherein the opposite of CCR1 chemical acceptor has formula (1),where each A is N or CH and at least one A is N; R¹ is halogen; R³ is selected from the group consisting of C₁₋₈ alkyl, C₃₋₈ cycloalkyl and C₂₋₈ alkenyl; and R⁸ is C₁₋₈ alkyl; or a pharmaceutically acceptable salt thereof. Claim 25: A kit for the treatment of a subject having a solid tumor cancer, said kit comprises a therapeutically effective amount of a chemokine receptor antagonist CCR1 and a therapeutically effective amount of a PD-1 inhibitor or inhibitor of PD-L1, with instructions for effective administration.